FrancophonIA/ELRC3.0 huggingface dataset:
English: The recommended dose of Apealea is 250 mg/m2 body surface area (BSA) given as an intravenous infusion over 1 hour followed by carboplatin every three weeks for six cycles.
Maltese: Id-doża rakkomandata ta' Apealea hija 250 mg/m2 tal-erja tas-superfiċje tal-ġisem (BSA) mogħtija bħala infużjoni ġol-vini għal siegħa segwita minn carboplatin kull tliet ġimgħat għal sitt ċikli.
English: Apealea is used to treat the following cancers in adults, in combination with another medicine called carboplatin:
Maltese: Apealea jintuża biex jittratta l-kanċers li ġejjin fl-adulti, flimkien ma' mediċina oħra msejħa carboplatin:
English: 00330 Helsinki
Maltese: 00330 Helsinki Finland
English: Critically important antimicrobials for human medicine - 5th rev. Geneva.
Maltese: Critically important antimicrobials for human medicine - 5th rev.
English: Zoetis UK Limited 5th Floor, 6 St.
Maltese: Zoetis UK Limited 5th Floor, 6
English: Andrew Street London EC4A 3AE United Kingdom
Maltese: London EC4A 3AE United Kingdom
English: Ireland Zoetis Belgium S.A 2nd Floor, Building 10
Maltese: L-Irlanda Zoetis Belgium S.A 2nd Floor, Building 10
English: Belgium Zoetis Belgium SA Rue Laid Burniat 1
Maltese: Il-Belġju Zoetis Belgium SA Rue Laid Burniat 1
English: Discussion of data available
Maltese: Diskussjoni tad-data disponibbli
English: 1348 Louvain-laNeuve
Maltese: 1348 Louvain-la-Neuve Belgium
English: ATC Vet Code: QJ01FF02
Maltese: QJ01FF02
English: In both studies significant differences were noted in mortality rates between birds treated with lincomycin (0% and 0.7%, respectively) and negative controls (14% and 7.5%, respectively).
Maltese: Fiż-żewġ studji ġew innotati differenzi sinifikanti fir-rati ta' mortalità bejn għasafar li ngħataw kura bil-linkomiċina (0% u 0.7%, rispettivament) u lkontrolli negattivi (14% u 7.5%, rispettivament).
English: Germany Zoetis Deutschland GmbH
Maltese: Il-Germanja Zoetis Deutschland GmbH Schellingstr.
English: Administration conditions: Administration under the control or direct responsibility of a veterinary surgeon.
Maltese: Kundizzjonijiet tal-amministrazzjoni: Amministrazzjoni taħt il-kontroll jew responsabbiltà diretta ta' kirurgu veterinarju.
English: Hungary Zoetis Hungary Kft. Budapest, Alkotás u.
Maltese: L-Ungerija Zoetis Hungary Kft. Budapest, Alkotás u. 53., 1123 Hungary
English: The oral absorption of lincomycin was found to be 53% ± 19%.
Maltese: L-assorbiment orali ta' lincomycin instab li hu 53% ± 19%.
English: 470,6 mg lincomycin HCl/g (corresponding to 400 mg lincomycin/g)
Maltese: 470,6 mg lincomycin HCl/g (jikkorrispondi ġ għal 400 mg lincomycin/g)
English: • Indications
Maltese: • Indikazzjonijiet
English: CVMP opinion for a referral procedure (EMEA/V/A/110) under Article 35 of Directive 2001/82/EC for veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and/or poultry - link procedure, the CVMP concluded that this indication should also be deleted from the product information for Lincocin.
Maltese: 1 CVMP opinion for a referral procedure (EMEA/V/A/110) under Article 35 of Directive 2001/82/EC for veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and/or poultry - link
English: Poland Zoetis Polska Sp. z o.o.
Maltese: Il-Polonja Zoetis Polska Sp. z o.o. Postępu 17B
English: Cherrywood Business Park
Maltese: Cherrywood Business Park Loughlinstown
English: MANUFACTURER'S BATCH NUMBER Lot {number}:
Maltese: NUMRU TAL-LOTT TAL-MANIFATTUR Lott {numru}:
English: Licence: CC BY-NC-SA 3.0 IGO - link
Maltese: Licence: CC
English: Lincomycin is active against some gram-positive bacteria (Clostridium perfringens) and mycoplasmas (Mycoplasma hyopneumoniae).
Maltese: Lincomycin huwa attiv kontra mikrobi Gram-pożittiv (Clostridium perfringens) u mycoplasmas (Mycoplasma hyopneumoniae).
English: Pack sizes:
Maltese: Żmien ta' tiżmim:
English: There is no specific antidote, treatment is symptomatic.
Maltese: M'hemmx antidote speċifiku, it-trattament huwa sintomatiku.
English: Lincocin 40% Lincomycin (as lincomycin hydrochloride)
Maltese: Lincocin 40% Lincomycin (bħala lincomycin hydrochloride)
English: Upon comparison to more recent EU isolates (2011-2016), the MIC distributions are similar, being tri-modal with peaks differing by one doubling dilution at the most.
Maltese: Meta mqabbla ma' iżolati aktar reċenti tal-UE (2011 -2016), id-distribuzzjonijiet tal-MIC huma simili, jiġifieri trimodali b'quċċati li jiddifferenzjaw l-aktar wara dilwizzjoni unika.
English: The excreta contained mostly unmetabolised lincomycin (60-85%) during treatment.
Maltese: L-eskrementi waqt it-trattament, l-aktar li kien fihom kien lincomycin mhux metaboliżat (60-85%).
English: Similar results were observed following single oral doses of 4.4 and 11.0 mg/kg body weight in pigs.
Maltese: Riżultati simili ġew osservati wara doża waħda ta' 4.4 u 11.0 mg/kg piż tal-ġisem fil-ħnieżer.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Maltese: - komuni ħafna (aktar minn wieħed f'10 annimali ttrattati li juru effetti mhux mixtieqa) - komuni (aktar minn wieħed iżda inqas minn 10 annimali f'100 annimal ittrattat) - mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f'1,000 annimal ittrattat) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal ittrattat) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal ittrattat, inklużi rapporti iżolati).
English: Lincomycin can potentiate neuromuscular effects of anaesthetics and muscle relaxants.
Maltese: Lincomycin jista' jqawwi l-effetti newromuskolari tal-anestetiċi u tal-muscle relaxants.
English: White high density polyethylene (HDPE) bottle containing 150 g or 1.5 kg powder for use in drinking water with a tamper evident low density polyethylene (LDPE) lid.
Maltese: Flixkun abjad high density polyethylene (HDPE) li fih 150 g jew 1.5 kg trab għall-użu fl-ilma tax-xorb b'għatu ta' low density polyethylene (LDPE) evidenti kontra t-tbagħbis Mhux id-daqsijiet kollha tal-pakkett jistgħu qegħdin fis-suq.
English: LABELLING
Maltese: MANIFATTURA
English: Peak serum levels were observed at 4 hours after dosing.
Maltese: Livelli massimi fis-sirum ġew osservati 4 sigħat wara d-doża.
English: The slaughter times (0 hours after 3 days of medication and 0, 6, 12 and 24 hours after 21 days of medication) were well distributed to support the proposed zero-day withdrawal period.
Maltese: Il-ħinijiet tal-qatla (0 sigħat wara 3 ijiem ta' medikazzjoni u 0, 6, 12 u 24 siegħa wara 21 jum ta' medikazzjoni) kienu mqassma sew biex jappoġġjaw il-perjodu ta' tiżmim propost ta' żero jiem.
English: Pharmacotherapeutic group: Antibacterials for systemic use; Lincosamides.
Maltese: Antibatteriċi għal użu sistemiku; Lincosamides.
English: • The inclusion of information about resistance status and warnings about prudent use as regards resistance, in SPC sections 4.4 ‘Special warnings for each target species', 4.5 (i) ‘Special precautions for use in animals' and 5.1 ‘Pharmacodynamic properties'.
Maltese: • L-inklużjoni ta' informazzjoni dwar l-istatus tar-reżistenza u twissijiet dwar l-użu prudenti firrigward tar-reżistenza, fis-sezzjonijiet tal-SPC 4.4 ‘Twissijiet speċjali għal kull speċi li għaliha hu indikat il-prodott', 4.5 (i) ‘Prekawzjonijiet speċjali għall-użu fl-annimali' u 5.1 ‘Kwalitajiet farmakodinamiċi'.
English: These conditions are usually selfcorrecting within 5-8 days without discontinuing the lincomycin treatment.
Maltese: Normalment dawn il-kundizzjonijiet imorru waħidhom fi żmien 5-8 ijiem mingħajr ma jitwaqqaf it-trattament bil-lincomycin.
English: Albiotic Pulver 400 mg/g zum Eingeben über das
Maltese: Albiotic Pulver 400 mg/g zum Eingeben über das Trinkwasser für Schweine
English: Macrolides, lincosamides and streptogramins antimicrobials are listed by WHO (2017)3 as critically important for the treatment of certain zoonotic infections in humans (such as Campylobacter infections).
Maltese: Id-WHO (2017)3 telenka l-antimikrobiċi makrolidi, linkosamidi u streptogramini bħala ta' importanza kritika għallkura ta' ċerti infezzjonijiet żoonotiċi fil-bnedmin (bħal infezzjonijiet b'Campylobacter).
English: Pigs, chickens
Maltese: Ħnieżer, tiġieġ
English: Strength
Maltese: UŻATI
English: • The revised harmonised SPC of Lincocin contains the necessary information to ensure the safe and effective use of the product.
Maltese: • L-SPC armonizzat rivedut ta' Lincocin fih l-informazzjoni meħtieġa biex jiġi żgurat l-użu sigur u effettiv tal-prodott.
English: There is often complete cross-resistance between lincomycin and clindamycin.
Maltese: Spiss hemm reżistenza nkroċjata kompleta bejn lincomycin u clindamycin.
English: Lincomycin (as lincomycin hydrochloride)
Maltese: Lincomycin (bħala lincomycin hydrochloride)
English: The description and validation of the GC/MS analytical method was considered acceptable.
Maltese: Id-deskrizzjoni u l-validazzjoni tal-metodu analitiku tal-GC/MS tqiesu li kienu aċċettabbli.
English: List of the names, pharmaceutical form, strength of the veterinary medicinal products, animal species, route of administration, marketing authorisation holders in the Member States
Maltese: Lista tal-ismijiet, għamla farmaċewtika, qawwa tal-prodott mediċinali veterinarju, speċi tal-annimali, mnejn jingħata, detenturi tal-awtorizzazzjoni għat-tqegħid fis-suq fl-Istati Membri
English: The active substance lincomycin is a lincosamide antibiotic and is produced by Streptomyces lincolnensis.
Maltese: Issustanza attiva linkomiċina hija antibijotiku linkosamid u tiġi prodotta minn Streptomyces lincolnensis.
English: Necrotic enteritis: 5 mg lincomycin per kg of body weight (corresponding to 12.5 mg product per kg bodyweight) for 7 consecutive days.
Maltese: Enterite nekrotika: 5 mg lincomycin għal kull kg piż tal-ġisem (li jikkorrispondu għal 12.5 mg talprodott għal kull kg piż tal-ġisem) għal 7 tijiem konsekuttivi.
English: Colloidal anhydrous silica Lactose monohydrate
Maltese: 6.1 Lista ta' ingredjenti Colloidal anhydrous silica Mono-idrat tal-lattożju
English: The bioavailability of lincomycin may decrease in the presence of gastric antacids or activated charcoal, pectin or kaolin.
Maltese: Il-bijodisponibilità ta' lincomycin tista' tonqos fil-presenza ta' antaċidi gastriċi u charcoal attivat, pectin jew kaolin.
English: Lincomycin is a lincosamide antibiotic derived from Streptomyces lincolnensis which inhibits protein synthesis.
Maltese: Lincomycin huwa antibijotiku tal-grupp lincosamide derivat minn Streptomyces lincolnensis li jtellef is-sinteżi tal-protejini.
English: Pigs, poultry (broilers)
Maltese: Ħnieżer, tiġieġ (tassimna)
English: Lincomycin binds to the 50S sub-unit of the bacterial ribosome close to the peptidyl transfer centre and interferes with the peptide chain elongation process by causing premature peptidyl-tRNA dissociation from the ribosome.
Maltese: Lincomycin jabbina mal-50S sub-unit tar-ribosome tal-mikrobu viċin tal peptidyl transfer centre u jtellef il-proċess ta' elongazzjoni tal-peptide chain billi jikkawża separazzjoni prematura tal-peptidyl-tRNA minn mar-ribosome.
English: Bottle of 150 g Bottle of 1.5 kg
Maltese: Flixkun ta' 150 g Flixkun ta' 1.5 kg
English: It is bacteriostatic and primarily active against Gram-positive bacteria (both aerobic and anaerobic), Gram-negative anaerobic bacteria and mycoplasma.
Maltese: Huwa batterjostatiku u primarjament attiv kontra batterji Grampożittivi (kemm aerobiċi u anaerobiċi), batterji anaerobiċi Gram-negattivi u mikoplażmi.
English: Allergic/hypersensitive reactions occur on rare occasions.
Maltese: Reazzjonijiet allerġiċi/ipersensittivi jistgħu iseħħu f'każijiet rari.
English: Meat and offal: 5 days.
Maltese: Laħam u ġewwieni tal-annimali: 5 tijiem.
English: The elimination half-life of lincomycin is greater than 3 hours.
Maltese: Il-half-life ta' eliminazzjoni ta' lincomycin hija aktar minn 3 sigħat.
English: Approximately 50% of lincomycin is metabolised in the liver.
Maltese: Bejn wieħed u ieħor 50% ta' lincomycin huwa mmetabolizzat fil-fwied.
English: The provided clinical data demonstrated that Lincocin was effective in the treatment and metaphylaxis of enzootic pneumonia caused by M. hyopneumoniae when administered at 10 mg lincomycin per kg of body weight for 21 consecutive days.
Maltese: Id-data klinika pprovduta wriet li Lincocin kien effettiv għall-kura u l-metafilassi ta' pulmonite enzootika kkawżata minn M. hyopneumoniae meta jingħata f'doża ta' 10 mg ta' linkomiċina għal kull kg tal-piż tal-ġisem għal 21 jum konsekuttivi.
English: Lincomycin and one unknown metabolite comprised >50% of the muscle residue at zero hours.
Maltese: Lincomycin u metabolit mhux magħruf iffurmaw >50% tar-residwu fil muskoli f'0 sigħat.
English: The clinical data provided indicated that Lincocin was effective for the treatment of swine dysentery caused by B. hyodysenteriae; however, the studies in question were conducted in the period 1977-1993 and the MICs of isolates were not determined in the majority of clinical studies submitted.
Maltese: Id-data klinika pprovduta indikat li Lincocin kien effettiv għall-kura ta' disinterija tal-ħnieżer ikkawżata minn B. hyodysenteriae; madankollu, l-istudji inkwistjoni saru fil-perjodu ta' bejn l-1977-1993 u fil-biċċa l-kbira tal-istudji kliniċi ppreżentati lMICs tal-iżolati ma kinux determinati.
English: Indeed, there was evidence, albeit from a subclinical infection model, that MIC values above those for the apparent wild-type population do not necessarily correlate to a lack of clinical effectiveness of lincomycin (Lanckriet et al., 2010)2.
Maltese: Tabilħaqq, kien hemm evidenza, għalkemm minn mudell subkliniku ta' infezzjoni, li valuri tal-MIC ogħla minn dawk għall-popolazzjoni apparenti tat-tip selvaġġ mhux bilfors huma korrelatati ma' nuqqas ta' effikaċja klinika ta' linkomiċina (Lanckriet et al., 2010)2.
English: For the treatment and metaphylaxis of necrotic enteritis caused by Clostridium perfringens.
Maltese: Trattament u metafilassi ta' enterite nekrotika kkawżata minn Clostridium perfringens.
English: One composite muscle sample out of three had residues slightly above the MRL (57 µg/kg versus 50 µg/kg).
Maltese: Terz tal-kampjuni aggregati tal-muskoli kellhom residwi kemmxejn ogħla mill-MRL (57 µg/kg kontra 50 µg/kg).
English: For example, the results of the study conducted by the marketing authorisation holder in 2016 with 92 European isolates showed a MIC range of 0.5 μg/ml to >256 μg/ml and a tri-modal MIC distribution for lincomycin against C. perfringens (peaks at 1 μg/ml, 8 μg/ml and >256 μg/ml), with the majority of isolates falling outside the apparent wild-type population.
Maltese: Pereżempju, ir-riżultati tal-istudju li saru mid-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq fl-2016 b'92 iżolat Ewropew urew firxa tal-MIC ta' 0.5 μg/ml sa >256 μg/ml u distribuzzjoni trimodali tal-MIC għal-linkomiċina kontra C. perfringens (quċċati f'1 μg/ml, 8 μg/ml u >256 μg/ml), bil-maġġoranza tal-iżolati jaqgħu barra mill-popolazzjoni tat-tip selvaġġ apparenti.
English: Co. Dublin
Maltese: Dublin
English: For the treatment and metaphylaxis of enzootic pneumonia caused by Mycoplasma hyopneumoniae.
Maltese: Kura u metafilassi ta' pulmonite enzootika kkawżata minn Mycoplasma hyopneumoniae.
English: Despite the lack of standardised procedures for MIC testing of antimicrobial agents against mycoplasmas and clinical breakpoints, based on the MIC data provided it could be concluded that the susceptibility pattern of M. hyopneumoniae to lincomycin has not changed significantly over the last 20-25 years.
Maltese: Minkejja n-nuqqas ta' proċeduri standardizzati għall-ittestjar tal-MIC ta' aġenti antimikrobiċi kontra mikoplażmi u n-nuqqas ta' valuri kritiċi, abbażi tad-data dwar il-MIC ipprovduta jista' jiġi konkluż li l-mudell ta' suxxettibbiltà ta' M. hyopneumoniae għal-linkomiċina ma nbidilx b'mod sinifikanti matul l-aħħar 20-25 sena.
English: Excipients: For the full list of excipients, see section 6.1.
Maltese: Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
English: Enzootic pneumonia: 10 mg lincomycin per kg of body weight (corresponding to 25 mg product per kg bodyweight) for 21 consecutive days.
Maltese: Pnewmonja enżootika: 10 mg lincomycin għal kull kg piż tal-ġisem (li jikkorrispondu għal 25 mg talprodott għal kull kg piż tal-ġisem) għal 21 ġurnata konsekuttiva.
English: Pharmacokinetic particulars
Maltese: Għamla farmaċewtika
English: Lincomycin is eliminated unchanged or in the form of various metabolites in bile and urine.
Maltese: Lincomycin huwa eliminat mingħajr tibdil jew f'forma ta' varji metaboliti fil-bile u fl-urina.
English: To support the proposed harmonised indication for treatment and metaphylaxis of necrotic enteritis caused by Clostridium perfringens, the marketing authorisation holder presented in vitro susceptibility data including a recent proprietary study from 2016, clinical studies and data from the scientific literature.
Maltese: B sostenn tal-indikazzjoni armonizzata proposta għall-kura u l-metafilassi ta' enterite nekrotika kkawżata minn Clostridium perfringens, id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq ippreżenta data dwar is-suxxettibbiltà in vitro, fosthom studju propjetarju reċenti mill-2016, studji kliniċi u data mil-letteratura xjentifika.
English: DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Maltese: METODU U MOD(I) TA' AMMINISTRAZZJONI
English: Pigs: Meat and offal: 1 day.
Maltese: Laħam u ġewwieni tal-annimali: 1 jum.
English: However, as the pharmacokinetic parameters were greater upon administration of the soluble powder, and it is generally recognised that soluble powders are likely to result in a better bioavailability of the active substance in comparison to in-feed formulations, the CVMP accepted that clinical results relating to the premix formulation could be extrapolated to the soluble powder.
Maltese: Madankollu, minħabba li l-parametri farmakokinetiċi kienu ogħla mal-għoti tat-trab solubbli, u huwa ġeneralment rikonoxxut li trab solubbli huwa aktar probabbli li jwassal għal bijodisponibbiltà aħjar tas-sustanza attiva meta mqabbel ma' formulazzjonijiet imħallta mal-għalf, is-CVMP aċċetta li r-riżultati kliniċi relatati mal-formulazzjoni lesta minn qabel jistgħu jiġu estrapolati għat-trab solubbli.
English: Pigs:
Maltese: Ħnieżer:
English: Average daily water intake (litre/animal)
Maltese: Medja tal-ilma meħud kuljum (litru/annimal)
English: Treatment and metaphylaxis of necrotic enteritis caused by Clostridium perfringens.
Maltese: Kura u metafilassi ta' enterite nekrotika kkawżata minn Clostridium perfringens.
English: In addition, in a recent referral procedure under Article 35 of Directive 2001/82/EC for all veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs or chickens (EMEA/V/A/110)1, the CVMP concluded that indications relating to swine dysentery caused by B. hyodysenteriae were not sufficiently supported and should be deleted from the product information.
Maltese: Barra minn hekk, fi proċedura ta' referenza reċenti skont l-Artikolu 35 tad-Direttiva 2001/82/KE għall-prodotti mediċinali veterinarji kollha li fihom kombinazzjoni ta' linkomiċina u spektinomiċina għall-għoti b'mod orali lill-ħnieżer jew lit-tiġieġ (EMEA/V/A/110)1, is-CVMP ikkonkluda li l-indikazzjonijiet dwar id-disinterija tal-ħnieżer ikkawżata minn B. hyodysenteriae ma kinux appoġġjati biżżejjed u għadhom jitħassru mill-informazzjoni dwar il-prodott.
English: A single oral administration of lincomycin hydrochloride, at dose levels of approximately 22, 55 and 100 mg/kg body weight in pigs, resulted in dose related lincomycin serum levels, detected for 24-36 hours after administration.
Maltese: Doża waħda ta' lincomycin amministrata mill-ħalq, f'livelli ta' dożi ta' 22, 55 u 100 mg/kg piż tal-ġisem fil-ħnieżer, irriżultaw f'livelli fis-sirum relatati mad-doża, mkejla għal 24-36 siegħa wara l-amministrazzjoni.
English: The dosage of 3.9 mg/kg body weight was investigated in another two trials with similar designs, under simulated natural conditions.
Maltese: Iddoża ta' 3.9 mg/kg tal-piż tal-ġisem kienet investigata f'żewġ provi oħra b'disinji simili, taħt kundizzjonijiet naturali simulati.
English: Antagonism may exist between lincomycin and macrolides such as erythromycin and other bactericidal antibiotics; concurrent use is therefore not recommended due to competitive binding at the 50S ribosomal subunit of the bacterial cell.
Maltese: Jista' jeżisti antagoniżmu bejn lincomycin u macrolides bħal erythromycin u antibijotiċi li joqtlu lmikrobi; l-użu fl-istess ħin mhux rakkomandat minħabba abbinar kompetittiv fil-50S ribosomal subunit taċ-ċellola tal-mikrobu.
English: An up-to-date residue depletion study was provided with a soluble powder containing a combination of lincomycin and spectinomycin, and the dose of lincomycin that was administered was approximately 3 to 5 times higher than the recommended dose for Lincocin.
Maltese: Ġie pprovdut studju aġġornat dwar it-tnaqqis tar-residwi bi trab solubbli li kien fih kombinazzjoni ta' linkomiċina u spektinomiċina, u d-doża ta' linkomiċina li ngħatat kienet madwar 3 sa 5 darbiet ogħla mid-doża rakkomandata għal Lincocin.
English: Withdrawal periods:
Maltese: Inkompatibilitajiet:
English: Do not administer, and do not allow access to water containing lincomycin, to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants as this could result in severe gastro- intestinal disturbance.
Maltese: T'amministrax, u tħallix aċċess għall-ilma li jkun fih il-lincomycin, lil fniek, ħamsters, fniek tal-indi, ċinċilla, żwiemel jew ruminanti billi dan jista' jirriżulta f'taqlib gastro-intestinali serju.
English: Lincocin 400 mg/g powder for use in drinking water Lincomycin (as lincomycin hydrochloride) STATEMENT OF ACTIVE SUBSTANCES Each g contains 400 mg lincomycin (as lincomycin hydrochloride).
Maltese: DIKJARAZZJONI TAS-SUSTANZA ATTIVA U SUSTANZI OĦRA Kull g fiha 400 mg lincomycin (bħala lincomycin hydrochloride)
English: Where possible, therapy should be based on local (regional, farm level) epidemiological information concerning the response of enzootic pneumonia/necrotic enteritis to treatment with lincomycin.”
Maltese: Fejn ikun possibbli, it-terapija għandha tkun ibbażata fuq informazzjoni epidemjoloġika lokali (reġjonali, fuq livell ta' razzett) dwar ir-rispons ta' pulmonite enzootika/enterite nekrotika għall-kura bil-linkomiċina.”
English: • Withdrawal periods.
Maltese: • Perjodi ta' tiżmim.
English: The in vitro data from published literature and from the marketing authorisation holder's own study indicated that the MIC distribution for lincomycin was wide and not unimodal.
Maltese: Id-data in vitro mil-letteratura ppubblikata u mill-istudju stess tad-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq indikat li d-distribuzzjoni tal-MIC għal-linkomiċina kienet wiesgħa u ma kinitx unimodali.
English: Lincocin has been shown to be efficacious for the treatment and metaphylaxis of enzootic pneumonia caused by M. hyopneumoniae in pigs.
Maltese: Lincocin intwera li huwa effikaċi għall-kura u l-metafilassi ta' pulmonite enzootika kkawżata minn M. hyopneumoniae fil-ħnieżer.
English: The susceptibility of Mycoplasma hyopneumoniae to antimicrobial agents is difficult to test in vitro owing to technical constraints.
Maltese: Is-suxxettibilità ta' Mycoplasma hyopneumoniae għal aġenti kontra l-mikrobi hija diffiċli biex tiġi vverifikata in vitro minħabba restrizzjonijiet tekniċi.
English: Dosage (mg product per kg body weight per day)
Maltese: Dożaġġ (mg prodott għal kull kg piż tal-ġisem kuljum)